Estimated life expectancy of Parkinson's patients compared with the UK population
- 1 December 2007
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 78 (12) , 1304-1309
- https://doi.org/10.1136/jnnp.2006.100107
Abstract
To calculate the best possible estimates for age specific life expectancy (LE) and anticipated age at the time of death (AAD) in patients with Parkinson's disease (PD) compared with the general population in the UK. These may be of greater value to patients than standardised mortality ratios (SMRs), which are usually reported in studies on mortality in PD. A literature review identified articles with data on age stratified life expectancy or SMRs to calculate estimations of LE using the Gompertz function and data on mortality and LE in the UK from the Office of National Statistics and Actuarial Department for the year 2003. Two UK studies and four from Western Europe were used to estimate LE and AAD for patients with PD from SMRs. The mean LEs of patients with PD compared with the general population were: 38 (SD 5) years for onset between 25 and 39 years compared with 49 (SD 5) years; 21 (SD 5) years for onset between 40 and 64 years compared with 31 (SD 7) years; and 5 (SD 4) years for onset age > or = 65 years compared with 9 (SD 5) years. The average AAD of patients with PD with onset between 25 and 39 years was 71 (SD 3) years and considerably lower than that of the general population (82 (SD 2) years). The difference between average AAD for older individuals with PD (onset > or = 65 years) and the general population was smaller, with an AAD of approximately 88 (SD 7) years compared with 91 (SD 5) years. The calculations showed that LE and AAD in PD are reduced for all onset ages but this reduction is greatest in individuals with a young onset. While the results are average estimates, these can provide useful indications of LE and AAD.Keywords
This publication has 50 references indexed in Scilit:
- Survival of Parkinson's disease patients in a large prospective cohort of male health professionalsMovement Disorders, 2006
- Parkinsonism in OntarioNeurology, 2001
- Ten-year follow-up of three different initial treatments in de-novo PDNeurology, 2001
- Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's diseaseMovement Disorders, 2001
- Prospective study of caffeine consumption and risk of Parkinson's disease in men and womenAnnals of Neurology, 2001
- Selegiline and mortality in subjects with Parkinson’s diseaseNeurology, 2000
- Parkinson Disease SurvivalArchives of Neurology, 2000
- Prognosis with Parkinson's disease in europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.2000
- Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's diseaseBMJ, 1995
- Fun with Gompertz.1991